PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28214453-0 2017 Reciprocal regulation of eNOS, H2S and CO-synthesizing enzymes in human atheroma: Correlation with plaque stability and effects of simvastatin. Simvastatin 131-142 nitric oxide synthase 3 Homo sapiens 25-29 29549671-0 2018 Lower levels of Caveolin-1 and higher levels of endothelial nitric oxide synthase are observed in abdominal aortic aneurysm patients treated with simvastatin. Simvastatin 146-157 nitric oxide synthase 3 Homo sapiens 48-81 29549671-1 2018 This study was undertaken to verify whether simvastatin modulates Cav-1/eNOS expression, and if this modulation is associated with changes in pro- and anti-inflammatory cytokine and Toll-like receptor 4 (TLR4) level in abdominal aortic aneurysm (AAA). Simvastatin 44-55 nitric oxide synthase 3 Homo sapiens 72-76 29549671-3 2018 Simvastatin treatment decreased Cav-1 (p<0.05) and increased eNOS expression (p<0.01) in the AAA wall. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 64-68 29549671-5 2018 The changes in Cav-1 and eNOS were associated with a trend towards decreased IL-6 and IL-17 concentration (p>0.05) and increased IL-10 concentration (p=0.055); however, TLR4 expression was unaffected, suggesting that simvastatin influences Cav-1 and eNOS in the AAA wall by other mechanisms. Simvastatin 220-231 nitric oxide synthase 3 Homo sapiens 25-29 29549671-6 2018 Simvastatin may modulate Cav-1 and eNOS expression in the aneurysmal wall, indicating a potentially beneficial role for statins in AAA patients. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 35-39 29210030-11 2018 Simvastatin and atorvastatin improve endothelial dysfunction mainly by enhancing endothelial nitric oxide synthase (eNOS) expression and phosphorylation and NO production. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 81-114 28214453-11 2017 Simvastatin decreased iNOS, HO-1, HIF-1alpha and CSE whilst it increased eNOS phosphorylation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 73-77 28214453-13 2017 Simvastatin, besides its known effect on eNOS upregulation, reduced the HIF-1alpha and its downstream targets. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 41-45 27091343-0 2016 Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase. Simvastatin 51-62 nitric oxide synthase 3 Homo sapiens 74-107 28161429-8 2017 Results of western blot showed SIM post-treatment increased significantly phosphor-eNOS (Ser1177) expression but no total eNOS expression. Simvastatin 31-34 nitric oxide synthase 3 Homo sapiens 83-87 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 nitric oxide synthase 3 Homo sapiens 96-100 26304753-0 2015 Role of phosphatase activity of soluble epoxide hydrolase in regulating simvastatin-activated endothelial nitric oxide synthase. Simvastatin 72-83 nitric oxide synthase 3 Homo sapiens 94-127 26304753-4 2015 Simvastatin, a clinical lipid-lowering drug, also has a pleiotropic effect on eNOS activation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 78-82 26304753-5 2015 However, whether sEH phosphatase is involved in simvastatin-activated eNOS activity remains elusive. Simvastatin 48-59 nitric oxide synthase 3 Homo sapiens 70-74 26304753-6 2015 We investigated the role of sEH phosphatase activity in simvastatin-mediated activation of eNOS in endothelial cells (ECs). Simvastatin 56-67 nitric oxide synthase 3 Homo sapiens 91-95 26304753-8 2015 In addition, pharmacological inhibition of sEH phosphatase or overexpressing the inactive phosphatase domain of sEH enhanced simvastatin-induced NO bioavailability, tube formation and phosphorylation of eNOS, Akt, and AMP-activated protein kinase (AMPK). Simvastatin 125-136 nitric oxide synthase 3 Homo sapiens 203-207 26304753-9 2015 In contrast, overexpressing the phosphatase domain of sEH limited the simvastatin-increased NO biosynthesis and eNOS phosphorylation at Ser1179. Simvastatin 70-81 nitric oxide synthase 3 Homo sapiens 112-116 26304753-10 2015 Simvastatin evoked epidermal growth factor receptor-c-Src-increased Tyr phosphorylation of sEH and formation of an sEH-Akt-AMPK-eNOS complex, which was abolished by the c-Src kinase inhibitor PP1 or c-Src dominant-negative mutant K298M. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 128-132 26304753-11 2015 These findings suggest that sEH phosphatase activity negatively regulates simvastatin-activated eNOS by impeding the Akt-AMPK-eNOS signaling cascade. Simvastatin 74-85 nitric oxide synthase 3 Homo sapiens 126-130 23108656-10 2012 Moreover, we observed that simvastatin attenuated tumor necrosis factor-alpha-induced upregulation of miR-155 and ameliorated the effects of tumor necrosis factor-alpha on eNOS expression and endothelium-dependent vasodilation. Simvastatin 27-38 nitric oxide synthase 3 Homo sapiens 172-176 23876348-0 2013 Simvastatin treatment increases nitrite levels in obese women: modulation by T(-786)C polymorphism of eNOS. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 102-106 20525309-10 2010 Simvastatin markedly increased NO release, vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and endothelial nitric oxide synthase (eNOS) expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 109-142 22792801-7 2012 They could enhance the NO content in cell culture supernatants, down-regulate the expression of Cav-1 and up-regulate the expression of eNOS at mRNA and protein levels, which was especially notable after treatment with serum containing TYTZF and simvastatin in large doses. Simvastatin 246-257 nitric oxide synthase 3 Homo sapiens 136-140 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 95-99 19513607-0 2009 Simvastatin increases the activity of endothelial nitric oxide synthase via enhancing phosphorylation. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 38-71 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 63-67 18221806-0 2009 Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Simvastatin 25-36 nitric oxide synthase 3 Homo sapiens 147-180 16002570-7 2005 Simvastatin additionally prevented pulmonary vascular remodeling and the changes in endothelial nitric oxide synthase expression induced by smoking. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 84-117 16002570-8 2005 In human lung microvascular endothelial cells, simvastatin increased expression of endothelial nitric oxide synthase mRNA. Simvastatin 47-58 nitric oxide synthase 3 Homo sapiens 83-116 12860247-7 2003 Human aortic endothelial cells incubated with simvastatin exhibited up to threefold higher intracellular oxidation of DHR-123 along with a twofold increase in total e-NOS protein. Simvastatin 46-57 nitric oxide synthase 3 Homo sapiens 165-170 11348878-2 2001 Here, we show that simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, within the therapeutic range (0.01 to 1 micromol/L) prevented the downregulation of eNOS mRNA and protein promoted by nLDL (180 mg cholesterol/dL, 48 hours) in human umbilical vein endothelial cells. Simvastatin 19-30 nitric oxide synthase 3 Homo sapiens 177-181 11348878-4 2001 Simvastatin significantly stabilized eNOS mRNA in cells treated with nLDL during 48 hours (eNOS mRNA half-life approximately 11 hours in controls versus >24 hours in nLDL per 0.1 micromol/L simvastatin-treated cells). Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 37-41 11348878-4 2001 Simvastatin significantly stabilized eNOS mRNA in cells treated with nLDL during 48 hours (eNOS mRNA half-life approximately 11 hours in controls versus >24 hours in nLDL per 0.1 micromol/L simvastatin-treated cells). Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 91-95 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 123-127 19513607-3 2009 In the present study, we investigated if simvastatin increases eNOS activity through its phosphorylation in 293 cells (293-eNOS) with stable expression of eNOS. Simvastatin 41-52 nitric oxide synthase 3 Homo sapiens 123-127 19513607-4 2009 The results showed that incubation of 293-eNOS cells with simvastatin (10 microm/L) for 2 h significantly increased in the activity of eNOS as shown by the conversion of L-arginine to L-citrulline (2889.70+/-201.51 versus 5630.18+/-218.75 pmol/min . Simvastatin 58-69 nitric oxide synthase 3 Homo sapiens 42-46 19513607-4 2009 The results showed that incubation of 293-eNOS cells with simvastatin (10 microm/L) for 2 h significantly increased in the activity of eNOS as shown by the conversion of L-arginine to L-citrulline (2889.70+/-201.51 versus 5630.18+/-218.75 pmol/min . Simvastatin 58-69 nitric oxide synthase 3 Homo sapiens 135-139 19513607-6 2009 Western blotting revealed that simvastatin increased phosphorylation of eNOS at 1177 (ser) and also 495 (thr) but did not affect the overall expression of eNOS or inducible NOS. Simvastatin 31-42 nitric oxide synthase 3 Homo sapiens 72-76 19513607-8 2009 These results suggest that simvastatin could stimulate the activity of eNOS via its phosphorylation by Akt and AMPK, which provides a new mechanism, other than lipid-lowering effect, for the cardiovascular protection of statins. Simvastatin 27-38 nitric oxide synthase 3 Homo sapiens 71-75 15864134-2 2005 We examined endothelial nitric oxide synthase (eNOS) mRNA levels, mRNA stability and the transcriptional activities of the eNOS gene in human umbilical vein endothelial cells treated with fluvastatin and simvastatin. Simvastatin 204-215 nitric oxide synthase 3 Homo sapiens 123-127 15864134-7 2005 Simvastatin increased eNOS mRNA levels and mRNA stability, but did not affect the transcriptional activity of the eNOS gene. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 22-26 15864134-10 2005 Simvastatin increased eNOS mRNA levels only by enhancing mRNA stability. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 22-26 15769392-6 2005 These effects of simvastatin and lovastatin on eNOS mRNA expression correlated with changes in nitric oxide production. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 47-51 14988829-2 2004 We hypothesized that simvastatin, which enhances Akt-dependent endothelial nitric oxide synthase phosphorylation, may increase hepatic nitric oxide release and decrease hepatic resistance in patients with cirrhosis and portal hypertension. Simvastatin 21-32 nitric oxide synthase 3 Homo sapiens 63-96 11693755-9 2001 Simvastatin reduced the TNF-alpha-related binding activity of neutrophil cytosolic proteins to eNOS mRNA, which was associated with its protective effect on eNOS protein expression. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 157-161 9395516-5 1997 In a concentration-dependent manner, simvastatin, and to a lesser extent, lovastatin, prevented the down-regulation of ecNOS expression by hypoxia. Simvastatin 37-48 nitric oxide synthase 3 Homo sapiens 119-124 9395516-6 1997 Simvastatin-induced changes in ecNOS expression correlated with changes in endothelial NO production and were reversed by treatment with L-mevalonate. Simvastatin 0-11 nitric oxide synthase 3 Homo sapiens 31-36 9395516-7 1997 Actinomycin D studies revealed that under hypoxic conditions, simvastatin increased ecNOS mRNA half-life from 13 to 38 h. Nuclear run-on studies showed that simvastatin had no effect on repression of ecNOS gene transcription by hypoxia. Simvastatin 62-73 nitric oxide synthase 3 Homo sapiens 84-89 9537338-5 1998 Both simvastatin (1 micromol/L) and lovastatin (10 micromol/L) upregulated ecNOS expression by 3.8-fold and 3.6-fold, respectively, and completely prevented its downregulation by ox-LDL. Simvastatin 5-16 nitric oxide synthase 3 Homo sapiens 75-80 9537338-6 1998 These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 32-37 9537338-6 1998 These effects of simvastatin on ecNOS expression correlated with changes in ecNOS activity. Simvastatin 17-28 nitric oxide synthase 3 Homo sapiens 76-81 9537338-7 1998 Although L-mevalonate alone did not affect ecNOS expression, cotreatment with L-mevalonate completely reversed ecNOS upregulation by simvastatin. Simvastatin 133-144 nitric oxide synthase 3 Homo sapiens 111-116 9537338-8 1998 Actinomycin D studies revealed that simvastatin stabilized ecNOS mRNA (tau1/2, 43 versus 35 hours). Simvastatin 36-47 nitric oxide synthase 3 Homo sapiens 59-64